Lineage Cell Therapeutics, Inc.
LCTX
$1.61
$0.031.90%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 130.40% | -2.59% | 96.38% | 4.02% | 37.36% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 130.40% | -2.59% | 96.38% | 4.02% | 37.36% |
| Cost of Revenue | -34.88% | -12.38% | 8.00% | 0.57% | -92.22% |
| Gross Profit | 151.45% | -2.02% | 74.73% | 2.70% | 222.66% |
| SG&A Expenses | 10.25% | -4.97% | 4.52% | -2.80% | 480.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.90% | -2.00% | 5.91% | -1.21% | 62.15% |
| Operating Income | -28.14% | 1.41% | 15.80% | 2.34% | -80.44% |
| Income Before Tax | -35.02% | -891.40% | -425.97% | 36.83% | 31.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 127.45% | -891.40% | -425.97% | 36.83% | 31.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -78.26% | 12.12% | -869.23% | -75.00% | 62.30% |
| Net Income | 126.00% | -881.58% | -428.89% | 36.73% | 31.46% |
| EBIT | -28.14% | 1.41% | 15.80% | 2.34% | -80.44% |
| EBITDA | -28.29% | 2.46% | 16.70% | 2.24% | -86.64% |
| EPS Basic | 126.47% | -708.07% | -337.38% | 48.88% | 50.18% |
| Normalized Basic EPS | -36.05% | -705.94% | -125.79% | 48.88% | -86.96% |
| EPS Diluted | 126.47% | -708.07% | -337.38% | 48.88% | 50.18% |
| Normalized Diluted EPS | -36.05% | -705.94% | -125.79% | 48.88% | -86.96% |
| Average Basic Shares Outstanding | -1.26% | 21.19% | 20.94% | 23.59% | 37.24% |
| Average Diluted Shares Outstanding | -1.26% | 21.19% | 20.94% | 23.59% | 37.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |